Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Asimadoline - Tioga Pharmaceuticals

Drug Profile

Asimadoline - Tioga Pharmaceuticals

Alternative Names: EMD-61753; EMR 63 320; ONO-3951

Latest Information Update: 22 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck KGaA
  • Developer Merck KGaA; Ono Pharmaceutical; Tioga Pharmaceuticals
  • Class Acetamides; Opioid analgesics; Pyrrolidines; Small molecules
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pruritus
  • Discontinued Irritable bowel syndrome; Pain; Postoperative ileus

Most Recent Events

  • 04 Dec 2017 Safety and efficacy data from a phase II clinical trial in Pruritus released by Tioga Pharmaceuticals
  • 06 Aug 2015 Discontinued - Phase-III for Irritable bowel syndrome in USA (PO)
  • 01 Jun 2015 Phase-II clinical trials in Pruritus (In adults, In the elderly) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top